Canada’s Intellectual Property Firm

PMPRB issues a Notice of Hearing for allegations of excessive pricing of PROCYSBI

Authored byLynn Ing

The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling or has sold PROCYSBI (cysteamine bitartrate) in any market in Canada at a price that, in the Board's opinion, is or was excessive; and if so, what order, if any, should be made to remedy the excessive pricing.

News Release; Notice of Hearing; Statement of Allegations of Board Staff